Heart Failure
Conditions
Interventions
Heart failure group (including National Human Brain Bank and PUMCH):NA
control group (from National Human Brain Bank):NA
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Heart failure group (PUMCH) inclusion: 1) symptoms or signs of heart failure; 2)Presence of cardiac structural or functional abnormalities assessed by echocardiography (LVEF15, moderate/severe ventricular hypertrophy, or moderate/severe valve stenosis or reflux, etc.); 3) at least one of the following: elevated BNP or NT-proBNP (Sinus rhythm BNP >= 35 pg/ml or NT-proBNP >= 125 pg/ml; Atrial fibrillation BNP >= 105pg/ml or NT-proBNP >= 365 pg/ml), objective evidence of cardiogenic pulmonary or systemic congestion obtained by imaging (e.g., chest radiograph or echocardiogram with high filling pressure) or hemodynamic measurements (e.g., right cardiac catheter) in a static or excited state. 2.Heart failure group (National Human Brain Bank) inclusion: The primary diagnosis in the cause of death or brief medical history of the organ donor includes "heart failure."; 3.Control Group (National Human Brain Bank) inclusion: 1) Age under 70 years (due to the high prevalence of heart failure in elderly patients); 2) Patients who died from non-cardiac causes (excluding those who died from cardiac causes such as sudden cardiac death, myocardial infarction, heart failure, cardiac arrest, etc.; preference is given to patients who died due to accidental events).
Exclusion criteria
Exclusion criteria: 1.Heart failure group (PUMCH) exclusion: 1)Heart failure confirmed through clinical assessment to be caused by systemic diseases includes severe systemic infections, highly active autoimmune diseases, uncontrolled hyperthyroidism, severe anemia, etc. 2)Heart failure confirmed through clinical assessment or myocardial biopsy pathology to be caused by the following special types of etiology includes: infiltrative cardiomyopathies (such as cardiac amyloidosis, glycogen storage diseases, hemochromatosis, etc.), myocarditis (such as infectious myocarditis, autoimmune myocarditis, inflammatory myopathies, eosinophilic myocarditis, immunotherapy-related myocarditis, etc.), constrictive pericarditis, and other special types of cardiomyopathies (such as hypertrophic obstructive cardiomyopathy, arrhythmogenic right ventricular dysplasia/right ventricular cardiomyopathy, genetic cardiomyopathies), etc. 3)History of heart transplantation; 2.Heart failure group (National Human Brain Bank) exclusion: 1) Exclude patients with severe systemic inflammatory conditions (e.g., septic shock, sepsis, active autoimmune diseases). 2) Exclude patients with confirmed rare or specific causes of heart failure, such as cardiac amyloidosis, fulminant myocarditis, hereditary cardiomyopathies, etc. 3) Other patients deemed unsuitable for inclusion based on clinical evaluation. 3.Control Group (National Human Brain Bank) exclusion: 1) Exclude patients with a brief clinical history indicating a diagnosis of heart failure or cardiomyopathy. 2) Exclude patients with severe systemic inflammatory conditions (e.g., septic shock, sepsis, active autoimmune diseases), vascular diseases (e.g., atherosclerotic cerebral infarction), renal failure, or those deemed unsuitable as control subjects based on clinical evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Levels of histone acylation in heart and kidney tissue; | — |
Countries
China
Contacts
Public ContactYaqun Teng
Peking Union Medical College Hospital
Outcome results
None listed